Introduction: The atypical antipsychotic quetiapine is known to induce weight gain and other metabolic complications. The underlying mechanisms are multifactorial and poorly understood with almost no information on the effect of dosage. Concerns were thus raised with the rise in low-dose quetiapine off-label prescription (i. e.,<150 mg/day).
Methods: In this study, we evaluated the influence of quetiapine dose for 474 patients included in PsyMetab and PsyClin studies on weight and metabolic parameter evolution. Weight, blood pressure, lipid, and glucose profiles were evaluated during a follow-up period of 3 months after treatment initiation.
Results: Significant dose-dependent metabolic alterations were observed. The daily dose was found to influence weight gain and increase the risk of undergoing clinically relevant weight gain (≥7% from baseline). It was also associated with a change in plasma levels of cholesterol (total cholesterol, LDL cholesterol, and HDL cholesterol) as well as with increased odds of developing hypertriglyceridemia, as well as total and LDL hypercholesterolemia. No impact of a dose increase on blood pressure and plasma glucose level was observed.
Discussion: The dose-dependent effect highlighted for weight gain and lipid alterations emphasizes the importance of prescribing the minimal effective dose. However, as the effect size of a dose increase on metabolic worsening is low, the potential harm of low-dose quetiapine should not be dismissed. Prescriptions must be carefully evaluated and regularly questioned in light of side effect onset.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-1525-2820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Quetiapine in the Prevention of ICU Delirium in Elderly Patients at a High Risk.
J Crit Care Med (Targu Mures)
October 2024
Department of Anesthesia, Intensive Care and Pain Management, Ain Shams University, Abbasiya, Cairo, Egypt.
Background: The aim of the present study was to denote the effectiveness of Quetiapine as additive to preventive bundle of delirium in elderly patients with multiple risks for delirium.
Patients And Methods: The study was performed on 90 elderly patients over 60 years. The patients were divided into Group Q (Quetiapine) and Group C (No Quetiapine).
Antipsychotic off-label use in the 21st century: An enduring public health concern.
Dialogues Clin Neurosci
December 2025
University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France.
Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms.
View Article and Find Full Text PDFSafety of Low-Dose Quetiapine for Insomnia in Older Adults.
Drugs Aging
January 2025
Pharmacy Outcomes Research Group, Kaiser Permanente, 12254 Bellflower Blvd, Downey, CA, 90242, USA.
Background And Objective: Quetiapine is a Food and Drug Administration (FDA) approved second-generation antipsychotic. It is also commonly used at low dose for its sedative properties to treat insomnia in the older population. Quetiapine at standard doses has been associated with increased risk of cerebrovascular events, cognitive decline, and mortality in patients with dementia, especially within older adults.
View Article and Find Full Text PDFManagement of Antenatal Agitation in a Tertiary Care Center in Central India: A Secondary Analysis.
Cureus
November 2024
Psychiatry, Mahatma Gandhi Memorial Medical College, Indore, IND.
Background The presence of psychiatric symptoms in pregnancy is a common occurrence that requires swift and effective management to avoid harm to self, caregivers, staff, and, above all, the reliant fetus. However, there is a dearth of knowledge, practical guidelines, and research in the context of managing agitated states of antenatal patients. To bridge this critical knowledge gap, this research endeavors to illuminate the practices surrounding the management of agitated pregnant women with respect to psychiatric emergencies in a tertiary care hospital.
View Article and Find Full Text PDFContrast-induced encephalopathy with visual and auditory hallucinations triggered by coronary angiography with iodixanol: a case report.
Egypt Heart J
December 2024
Department of Interventional Cardiology and Internal Diseases, Military Institute of Medicine - National Research Institute, Zegrzyńska 8 Street, 05-119, Legionowo, Poland.
Article Synopsis
- Contrast-induced encephalopathy (CIE) is a rare but serious complication after coronary angiography, often presenting as transient cortical blindness; however, this case reports the first instance of CIE accompanied by visual and auditory hallucinations.
- An 80-year-old female patient experienced confusion and hallucinations following an elective coronary procedure, after complications were encountered during the angiography; stroke was initially suspected but ruled out through MRI.
- The patient was diagnosed with CIE and treated with sedation and quetiapine for her hallucinations, ultimately leading to the resolution of her symptoms within five days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!